NCI Is Testing Thalidomide to Prevent Colorectal Cancer Recurrence
BETHESDA, Md-The National Cancer Institute has launched a double-blind study of thalidomide (Thalomid) to test its effectiveness in preventing colorectal cancer recurrence. The study will enroll 94 patients who will make their medical visits at the National Institutes of Health. Half will receive thalidomide, and half will get a placebo.
BETHESDA, MdThe National Cancer Institute has launched a double-blind study of thalidomide (Thalomid) to test its effectiveness in preventing colorectal cancer recurrence. The study will enroll 94 patients who will make their medical visits at the National Institutes of Health. Half will receive thalidomide, and half will get a placebo.
Eligible patients are men and women with local recurrence in the colon following surgery or whose colon cancer has metastasized but is operable.
Patients will begin thalidomide at 100 mg/day, with escalation up to 300 mg/day if tolerated. Because of thalidomides sedative effect, patients will take their pills once daily at bedtime. Patients will remain in the study up to 2 years.
Thalidomide prevents the growth of new blood vessels, such as those needed for a tumor to grow. Because of its well-known ability to cause severe birth defects, both men and women participating in the trial must agree to use two types of contraception.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma
November 9th 2023Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.
Domvanalimab Plus Zimberelimab Improve Efficacy in Gastrointestinal Cancers
November 7th 2023Results from arm A1 of the phase 2 EDGE-Gastric study indicate that patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma experienced improved responses after receiving domvanalimab/zimberelimab.
